Vistas | |
---|---|
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 170 |
diciembre 2024 | enero 2025 | febrero 2025 | marzo 2025 | abril 2025 | mayo 2025 | junio 2025 | |
---|---|---|---|---|---|---|---|
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 5 | 5 | 9 | 9 | 14 | 3 | 0 |
Vistas |
---|
Vistas |
---|